Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of RNA-based
therapeutics, today announced that it has initiated dosing in a clinical
study of eteplirsen, the Company's lead exon-skipping therapeutic
candidate for the treatment of Duchenne muscular dystrophy (DMD), in
patients who are non-ambulant or who have advanced DMD and don't meet a
minimum 6-minute walk test score at baseline.
for Sarepta Therapeutics Announces First Patient Dosed in Study of Eteplirsen in Non-Ambulant Patients with Duchenne Muscular Dystrophy investment picks